
    
      This is a phase 1, randomized, two-part, double-blind, placebo-controlled, dose-escalation,
      first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics
      and immunogenicity of AK120 in healthy subjects (part 1, single ascending dose) and subjects
      with moderate- to- severe atopic dermatitis(part 2, multiple ascending dose)
    
  